Your shopping cart is currently empty

Tizaterkib (AZD-0364) is a potent and selective ERK2 inhibitor.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $96 | In Stock | In Stock | |
| 2 mg | $139 | In Stock | In Stock | |
| 5 mg | $231 | In Stock | In Stock | |
| 10 mg | $368 | In Stock | In Stock | |
| 25 mg | $653 | In Stock | In Stock | |
| 50 mg | $937 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $242 | In Stock | In Stock |
| Description | Tizaterkib (AZD-0364) is a potent and selective ERK2 inhibitor. |
| Targets&IC50 | ERK2:0.6 nM |
| In vitro | AZD-0364 is measured in the ERK2 mass spectrometry and A375 phospho-p90RSK assays (IC50s: 0.6 nM and 5.7 nM). AZD-0364 can inhibit the growth of a panel of cancer cell lines (A549, H2122, H2009, and Calu6 cell lines) with KRAS mutations as monotherapy. |
| In vivo | In the A549 xenograft model, Selumetinib is dosed twice daily (BiD) 8 hours apart and AZD-0364 ethanesulfonic acid is dosed once daily (QD) 4 hours after the first Selumetinib dose. Both compounds are dosed continuously for 3 weeks. Both vehicles are dosed in the vehicle group. Both Selumetinib and AZD-0364 ethanesulfonic acid reduce tumor growth relative to vehicle-only control. The combination of Selumetinib and AZD-0364 ethanesulfonic acid results in a reduction in tumor growth. |
| Synonyms | AZD-0364 |
| Molecular Weight | 494.5 |
| Formula | C24H24F2N8O2 |
| Cas No. | 2097416-76-5 |
| Smiles | COC[C@H]1Cn2cc(nc2C(=O)N1Cc1ccc(F)c(F)c1)-c1nc(Nc2ccnn2C)ncc1C |
| Relative Density. | 1.45 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (202.22 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 3.3 mg/mL (6.67 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.